Sort
21,281 grants matching “influenza”
Engineering Protein Antigens and their Presentation from Multivalent Scaffolds
$816,638Ravi S Kane · Georgia Institute Of Technology · R01 · FY2024 · AI
Mechanistic studies of nucleic acid enzymes involved in DNA replication, transcription, and innate immunity
$816,553Smita S Patel · Rbhs-Robert Wood Johnson Medical School · R35 · FY2018 · GM
Clinical Core
$816,428Cornelia L Dekker · Stanford University · U19 · FY2013 · AI
Defining parameters to induce breadth in knockin mice expressing HIV bnAb precursors
$816,195Laurent Karl Verkoczy · San Diego Biomedical Research Institute · R01 · FY2018 · AI
COVID-19 Epidemiology and Immune-Pathogenesis in Pregnant Women, Mothers and Children
$816,161Mary A Staat · Cincinnati Childrens Hosp Med Ctr · U01 · FY2022 · AI
Development/production of seasonal, pandemic and universa influenza DNA vaccines
$816,079Richard Schwartz · National Institute Of Allergy And Infectious Diseases · ZIB · FY2011 · AI
Development/production of seasonal and pandemic influenza DNA vaccines
$816,079Richard Schwartz · National Institute Of Allergy And Infectious Diseases · ZIB · FY2010 · AI
VTEU: Phase I Influenza Vaccine Clinical Trial
$815,947Daniel Hoft · Saint Louis University · N01 · FY2016 · AI
Metabolism, infection and immunity in inborn errors of metabolism
$815,546Peter McGuire · National Human Genome Research Institute · ZIA · FY2015 · HG
Antibody Responses in Aging SIV Infected Monkeys
$815,288Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2018 · AI
Project 1: Mechanisms of innate sensing and pathogenesis of SARS-CoV-2
$815,251Andrea L Cox · Johns Hopkins University · U54 · FY2020 · CA
Technology Development for 3D Electron Microscopy
$814,930Sriram Subramaniam · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
HIV neutralization and mechanisms of cellular entry
$814,930Sriram Subramaniam · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Molecular basis and protective efficacy of cross-neutralizing antibodies against four major respiratory viruses
$814,880Jim Boonyaratanakornkit · Fred Hutchinson Cancer Center · R01 · FY2024 · AI
Molecular basis and protective efficacy of cross-neutralizing antibodies against four major respiratory viruses
$814,880Jim Boonyaratanakornkit · Fred Hutchinson Cancer Center · R01 · FY2023 · AI
Immunogenetics of COVID-19 Immune Response
$814,873Richard B Kennedy · Mayo Clinic Rochester · R01 · FY2024 · AI
Vaccines to Induce Functional Antibodies Targeting the V2 Loop
$814,846Susan B Zolla-Pazner · New York University School Of Medicine · P01 · FY2017 · AI
Balancing epithelial cell resistance and resilience to respiratory viral infections
$814,724Jose Manuel Ordovas-Montanes · Boston Children'S Hospital · R01 · FY2024 · HL
Antibody Responses in Aging SIV Infected Monkeys
$814,638Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2016 · AI
Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients
$814,262Natasha Bassam Halasa · Vanderbilt University Medical Center · U01 · FY2023 · AI
Basic and clinical studies in immune function and metabolism
$814,165Peter McGuire · National Human Genome Research Institute · ZIA · FY2013 · HG
Patterning of Transcription Factor Activity in T cells During Influenza Infection
$813,906Rajat Varma · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
Immune Dysfunction in HIV+ Opioid Users
$813,855Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2021 · DA
Accelerated Viral Inhibition Assay
$813,763Maryna C Eichelberger · Virion Systems, Inc. · R01 · FY2006 · AI
Preclinical development of an immunomodulatory agent capable of mitigating influenza related hypercytokinemia
$813,514Jodi K Craigo · Cytoagents, Inc. · R44 · FY2021 · AI